PTX3 and aspergillosis: Several reports have described the therapeutic effect of recombinant PTX3 in the models of aspergillosis [25, 26, 27]; of P. aeruginosa acute and chronic lung infections [17, 28, 29]; of acute respiratory syndrome [30] and of influenza virus lung infection [31]